Connect with us

Hi, what are you looking for?

News

Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating (NASDAQ:RPRX)

On 08/08/2024, Royalty Pharma plc (NASDAQ:RPRX) presented its Q2 earnings. Following a solid Q1, the company raised its 2024 outlook, with Portfolio Receipts expected to achieve $2.7/2.75 billion results. We positively view this announcement; however, today, we decided to focus on an ongoing downside.

Read the full article here

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Videos

Watch full video on YouTube

Videos

Watch full video on YouTube

Videos

Watch full video on YouTube